StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.20 | $3.72 | -11.43% | 2.6M |
| 05-12 | $3.80 | $3.62 | -4.74% | 0.8M |
| 05-13 | $3.62 | $3.96 | +9.39% | 0.8M |
| 05-14 | $4.00 | $3.89 | -2.75% | 0.7M |
| 05-15 | $3.84 | $3.70 | -3.65% | 0.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for SABS.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $1.32M | $1.21M | $1.21M |
Operating Income | $-48.95M | $-42.91M | $-32.90M | $-21.59M |
Net Income | $13.27M | $-34.11M | $-22.71M | $-7.34M |
EPS (Diluted) | $-0.79 | $-3.68 | $-2.45 | $-1.34 |
Total Assets | $172.81M | $44.20M | $53.80M | $61.89M |
Total Liabilities | $21.32M | $18.23M | $16.89M | $15.77M |
Cash & Equivalents | $10.50M | $8.90M | $9.17M | $17.24M |
Free Cash Flow OCF − CapEx | $-45.71M | $-34.63M | $-25.04M | $-18.65M |
Shares Outstanding | 47.61M | 9.29M | 9.23M | 9.23M |
Fundamentals not available for SABS.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.